Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Clinical and Dopamine Transporter Imaging Characteristics of Leucine- Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study.

Simuni T, Brumm MC, Uribe L, Caspell-Garcia C, Coffey CS, Siderowf A, Alcalay R, Trojanowski JQ, Shaw LM, Seibyl J, Singleton A, Toga AW, Galasko D, Foroud T, Nudelman K, Tosun-Turgut D, Poston K, Weintraub D, Mollenhauer B, Tanner CM, Kieburtz K, Chahine LM, Reimer A, Hutten S, Bressman S, Marek K; Parkinson's Progression Markers Initiative Investigators.

Mov Disord. 2020 Feb 19. doi: 10.1002/mds.27989. [Epub ahead of print]

PMID:
32073681
2.

An Assessment of LRRK2 Serine 935 Phosphorylation in Human Peripheral Blood Mononuclear Cells in Idiopathic Parkinson's Disease and G2019S LRRK2 Cohorts.

Padmanabhan S, Lanz TA, Gorman D, Wolfe M, Joyce A, Cabrera C, Lawrence-Henderson R, Levers N, Joshi N, Ma T, Liong C, Narayan S, Alcalay RN, Hutten SJ, Baptista MAS, Merchant K.

J Parkinsons Dis. 2020 Jan 28. doi: 10.3233/JPD-191786. [Epub ahead of print]

PMID:
32007961
3.

Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.

Simuni T, Uribe L, Cho HR, Caspell-Garcia C, Coffey CS, Siderowf A, Trojanowski JQ, Shaw LM, Seibyl J, Singleton A, Toga AW, Galasko D, Foroud T, Tosun D, Poston K, Weintraub D, Mollenhauer B, Tanner CM, Kieburtz K, Chahine LM, Reimer A, Hutten SJ, Bressman S, Marek K; PPMI Investigators.

Lancet Neurol. 2020 Jan;19(1):71-80. doi: 10.1016/S1474-4422(19)30319-9. Epub 2019 Oct 31.

PMID:
31678032
4.

Genomewide association study of Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohorts.

Iwaki H, Blauwendraat C, Leonard HL, Kim JJ, Liu G, Maple-Grødem J, Corvol JC, Pihlstrøm L, van Nimwegen M, Hutten SJ, Nguyen KH, Rick J, Eberly S, Faghri F, Auinger P, Scott KM, Wijeyekoon R, Van Deerlin VM, Hernandez DG, Gibbs JR; International Parkinson's Disease Genomics Consortium, Chitrala KN, Day-Williams AG, Brice A, Alves G, Noyce AJ, Tysnes OB, Evans JR, Breen DP, Estrada K, Wegel CE, Danjou F, Simon DK, Andreassen O, Ravina B, Toft M, Heutink P, Bloem BR, Weintraub D, Barker RA, Williams-Gray CH, van de Warrenburg BP, Van Hilten JJ, Scherzer CR, Singleton AB, Nalls MA.

Mov Disord. 2019 Dec;34(12):1839-1850. doi: 10.1002/mds.27845. Epub 2019 Sep 10.

PMID:
31505070
5.

RAN translation down.

Hutten S, Dormann D.

Nat Neurosci. 2019 Sep;22(9):1379-1380. doi: 10.1038/s41593-019-0482-4. No abstract available.

PMID:
31427772
6.

Genetic risk of Parkinson disease and progression:: An analysis of 13 longitudinal cohorts.

Iwaki H, Blauwendraat C, Leonard HL, Liu G, Maple-Grødem J, Corvol JC, Pihlstrøm L, van Nimwegen M, Hutten SJ, Nguyen KH, Rick J, Eberly S, Faghri F, Auinger P, Scott KM, Wijeyekoon R, Van Deerlin VM, Hernandez DG, Day-Williams AG, Brice A, Alves G, Noyce AJ, Tysnes OB, Evans JR, Breen DP, Estrada K, Wegel CE, Danjou F, Simon DK, Ravina B, Toft M, Heutink P, Bloem BR, Weintraub D, Barker RA, Williams-Gray CH, van de Warrenburg BP, Van Hilten JJ, Scherzer CR, Singleton AB, Nalls MA.

Neurol Genet. 2019 Jul 9;5(4):e348. doi: 10.1212/NXG.0000000000000348. eCollection 2019 Aug. Erratum in: Neurol Genet. 2019 Aug 15;5(4):e354.

7.

Live cell imaging reveals 3'-UTR dependent mRNA sorting to synapses.

Bauer KE, Segura I, Gaspar I, Scheuss V, Illig C, Ammer G, Hutten S, Basyuk E, Fernández-Moya SM, Ehses J, Bertrand E, Kiebler MA.

Nat Commun. 2019 Jul 18;10(1):3178. doi: 10.1038/s41467-019-11123-x.

8.

Lysine/RNA-interactions drive and regulate biomolecular condensation.

Ukmar-Godec T, Hutten S, Grieshop MP, Rezaei-Ghaleh N, Cima-Omori MS, Biernat J, Mandelkow E, Söding J, Dormann D, Zweckstetter M.

Nat Commun. 2019 Jul 2;10(1):2909. doi: 10.1038/s41467-019-10792-y.

9.

Nucleocytoplasmic transport defects in neurodegeneration - Cause or consequence?

Hutten S, Dormann D.

Semin Cell Dev Biol. 2019 Jun 5. pii: S1084-9521(18)30190-3. doi: 10.1016/j.semcdb.2019.05.020. [Epub ahead of print] Review.

PMID:
31152789
10.

Comparative study of cerebrospinal fluid α-synuclein seeding aggregation assays for diagnosis of Parkinson's disease.

Kang UJ, Boehme AK, Fairfoul G, Shahnawaz M, Ma TC, Hutten SJ, Green A, Soto C.

Mov Disord. 2019 Apr;34(4):536-544. doi: 10.1002/mds.27646. Epub 2019 Mar 6.

11.

Interaction modulation through arrays of clustered methyl-arginine protein modifications.

Woodsmith J, Casado-Medrano V, Benlasfer N, Eccles RL, Hutten S, Heine CL, Thormann V, Abou-Ajram C, Rocks O, Dormann D, Stelzl U.

Life Sci Alliance. 2018 Sep 21;1(5):e201800178. doi: 10.26508/lsa.201800178. eCollection 2018 Oct.

12.

A Proposed Roadmap for Parkinson's Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein.

Merchant KM, Cedarbaum JM, Brundin P, Dave KD, Eberling J, Espay AJ, Hutten SJ, Javidnia M, Luthman J, Maetzler W, Menalled L, Reimer AN, Stoessl AJ, Weiner DM; The Michael J. Fox Foundation Alpha Synuclein Clinical Path Working Group.

J Parkinsons Dis. 2019;9(1):31-61. doi: 10.3233/JPD-181471.

13.

Antibody-based methods for the measurement of α-synuclein concentration in human cerebrospinal fluid - method comparison and round robin study.

Mollenhauer B, Bowman FD, Drake D, Duong J, Blennow K, El-Agnaf O, Shaw LM, Masucci J, Taylor P, Umek RM, Dunty JM, Smith CL, Stoops E, Vanderstichele H, Schmid AW, Moniatte M, Zhang J, Kruse N, Lashuel HA, Teunissen C, Schubert T, Dave KD, Hutten SJ, Zetterberg H.

J Neurochem. 2019 Apr;149(1):126-138. doi: 10.1111/jnc.14569. Epub 2018 Nov 13.

14.

CRISPR-enhanced engineering of therapy-sensitive cancer cells for self-targeting of primary and metastatic tumors.

Reinshagen C, Bhere D, Choi SH, Hutten S, Nesterenko I, Wakimoto H, Le Roux E, Rizvi A, Du W, Minicucci C, Shah K.

Sci Transl Med. 2018 Jul 11;10(449). pii: eaao3240. doi: 10.1126/scitranslmed.aao3240.

PMID:
29997250
15.

Nuclear egress of TDP-43 and FUS occurs independently of Exportin-1/CRM1.

Ederle H, Funk C, Abou-Ajram C, Hutten S, Funk EBE, Kehlenbach RH, Bailer SM, Dormann D.

Sci Rep. 2018 May 4;8(1):7084. doi: 10.1038/s41598-018-25007-5.

16.

Phase Separation of FUS Is Suppressed by Its Nuclear Import Receptor and Arginine Methylation.

Hofweber M, Hutten S, Bourgeois B, Spreitzer E, Niedner-Boblenz A, Schifferer M, Ruepp MD, Simons M, Niessing D, Madl T, Dormann D.

Cell. 2018 Apr 19;173(3):706-719.e13. doi: 10.1016/j.cell.2018.03.004.

17.

A user's guide for α-synuclein biomarker studies in biological fluids: Perianalytical considerations.

Mollenhauer B, Batrla R, El-Agnaf O, Galasko DR, Lashuel HA, Merchant KM, Shaw LM, Selkoe DJ, Umek R, Vanderstichele H, Zetterberg H, Zhang J, Caspell-Garcia C, Coffey C, Hutten SJ, Frasier M, Taylor P; Investigating Synuclein Consortium of the Michael J. Fox Foundation for Parkinson's Research.

Mov Disord. 2017 Aug;32(8):1117-1130. doi: 10.1002/mds.27090. Epub 2017 Jul 22. Review.

18.

Dexamethasone-conjugated DNA nanotubes as anti-inflammatory agents in vivo.

Sellner S, Kocabey S, Zhang T, Nekolla K, Hutten S, Krombach F, Liedl T, Rehberg M.

Biomaterials. 2017 Jul;134:78-90. doi: 10.1016/j.biomaterials.2017.04.031. Epub 2017 Apr 17.

PMID:
28458030
19.

Visualization of BRI1 and SERK3/BAK1 Nanoclusters in Arabidopsis Roots.

Hutten SJ, Hamers DS, Aan den Toorn M, van Esse W, Nolles A, Bücherl CA, de Vries SC, Hohlbein J, Borst JW.

PLoS One. 2017 Jan 23;12(1):e0169905. doi: 10.1371/journal.pone.0169905. eCollection 2017.

20.

The Search for a Peripheral Biopsy Indicator of α-Synuclein Pathology for Parkinson Disease.

Lee JM, Derkinderen P, Kordower JH, Freeman R, Munoz DG, Kremer T, Zago W, Hutten SJ, Adler CH, Serrano GE, Beach TG.

J Neuropathol Exp Neurol. 2017 Jan 1;76(1):2-15. doi: 10.1093/jnen/nlw103. Review.

PMID:
28069931
21.

hnRNPA2/B1 Function in Neurodegeneration: It's a Gain, Not a Loss.

Hutten S, Dormann D.

Neuron. 2016 Nov 23;92(4):672-674. doi: 10.1016/j.neuron.2016.11.014.

22.

Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study.

Nalls MA, McLean CY, Rick J, Eberly S, Hutten SJ, Gwinn K, Sutherland M, Martinez M, Heutink P, Williams NM, Hardy J, Gasser T, Brice A, Price TR, Nicolas A, Keller MF, Molony C, Gibbs JR, Chen-Plotkin A, Suh E, Letson C, Fiandaca MS, Mapstone M, Federoff HJ, Noyce AJ, Morris H, Van Deerlin VM, Weintraub D, Zabetian C, Hernandez DG, Lesage S, Mullins M, Conley ED, Northover CA, Frasier M, Marek K, Day-Williams AG, Stone DJ, Ioannidis JP, Singleton AB; Parkinson's Disease Biomarkers Program and Parkinson's Progression Marker Initiative investigators.

Lancet Neurol. 2015 Oct;14(10):1002-9. doi: 10.1016/S1474-4422(15)00178-7. Epub 2015 Aug 10.

23.

Time-lapse imaging of nuclear bodies.

Hutten S, Swift S, Lamond AI.

Methods Mol Biol. 2015;1262:55-67. doi: 10.1007/978-1-4939-2253-6_4.

PMID:
25555575
24.

Unmasking the messenger.

Hutten S, Sharangdhar T, Kiebler M.

RNA Biol. 2014;11(8):992-7. doi: 10.4161/rna.32091. Epub 2014 Oct 31. Review.

25.

Importin 7 and Nup358 promote nuclear import of the protein component of human telomerase.

Frohnert C, Hutten S, Wälde S, Nath A, Kehlenbach RH.

PLoS One. 2014 Feb 20;9(2):e88887. doi: 10.1371/journal.pone.0088887. eCollection 2014.

26.

A role for the Cajal-body-associated SUMO isopeptidase USPL1 in snRNA transcription mediated by RNA polymerase II.

Hutten S, Chachami G, Winter U, Melchior F, Lamond AI.

J Cell Sci. 2014 Mar 1;127(Pt 5):1065-78. doi: 10.1242/jcs.141788. Epub 2014 Jan 10.

27.

The nucleoporin Nup358/RanBP2 promotes nuclear import in a cargo- and transport receptor-specific manner.

Wälde S, Thakar K, Hutten S, Spillner C, Nath A, Rothbauer U, Wiemann S, Kehlenbach RH.

Traffic. 2012 Feb;13(2):218-33. doi: 10.1111/j.1600-0854.2011.01302.x. Epub 2011 Nov 21.

28.

An intranucleolar body associated with rDNA.

Hutten S, Prescott A, James J, Riesenberg S, Boulon S, Lam YW, Lamond AI.

Chromosoma. 2011 Oct;120(5):481-99. doi: 10.1007/s00412-011-0327-8. Epub 2011 Jun 23.

29.

The nucleolus under stress.

Boulon S, Westman BJ, Hutten S, Boisvert FM, Lamond AI.

Mol Cell. 2010 Oct 22;40(2):216-27. doi: 10.1016/j.molcel.2010.09.024. Review.

30.

A proteomic screen for nucleolar SUMO targets shows SUMOylation modulates the function of Nop5/Nop58.

Westman BJ, Verheggen C, Hutten S, Lam YW, Bertrand E, Lamond AI.

Mol Cell. 2010 Aug 27;39(4):618-31. doi: 10.1016/j.molcel.2010.07.025.

31.

The nuclear pore component Nup358 promotes transportin-dependent nuclear import.

Hutten S, Wälde S, Spillner C, Hauber J, Kehlenbach RH.

J Cell Sci. 2009 Apr 15;122(Pt 8):1100-10. doi: 10.1242/jcs.040154. Epub 2009 Mar 19.

32.

The Nup358-RanGAP complex is required for efficient importin alpha/beta-dependent nuclear import.

Hutten S, Flotho A, Melchior F, Kehlenbach RH.

Mol Biol Cell. 2008 May;19(5):2300-10. doi: 10.1091/mbc.E07-12-1279. Epub 2008 Feb 27.

33.

CRM1-mediated nuclear export: to the pore and beyond.

Hutten S, Kehlenbach RH.

Trends Cell Biol. 2007 Apr;17(4):193-201. Epub 2007 Feb 20.

PMID:
17317185
34.

Nup214 is required for CRM1-dependent nuclear protein export in vivo.

Hutten S, Kehlenbach RH.

Mol Cell Biol. 2006 Sep;26(18):6772-85.

Supplemental Content

Loading ...
Support Center